Despite the high prevalence of tuberculosis (TB) in developing countries, primary pancreatic TB is a rare entity. TB in pancreas may present as acute or chronic pancreatitis, pancreatic abscesses, and as discrete pancreatic mass mimicking malignancy, thus making it a diagnostic challenge. [1] We present a case of pancreatic TB in an immunocompetent patient with a mass resemble malignancy and negative quantiferone test.
fat planes and possible infiltration of stomach, left lobe of the liver and encasing coeliac vessels, and portal vein. it also show multiple peripancreatic and reteroperitoneal lymphnodes [ Figure 1 ].
Endoscopic ultrasound (EUS) with fine needle aspiration of the pancreatic head mass was performed [ Figure 2 ]. Sonographically, there was a 3 cm × 3 cm necrotic mass within the pancreas body with multiple small and large peripancreatic lymph nodes. On-site cytologic and histopathologic, evaluation of the biopsy specimen revealed the presence of inflammation with no evidence of malignancy. Polymerase chain reaction (PCR) and culture for acid-fast bacilli were positive for Mycobacterium tuberculosis (MTB).
Given the diagnosis of pancreatic TB, testing for human immunodeficiency virus was negative. The patient was started on antituberculosis therapy with isoniazid, rifampin, pyrazinamide, and ethambutol. The patient traveled back to his country planning to complete the treatment course for 6 month.
dIscussIon
MTB is an intracellular pathogen that can live in the dormant state in the living tissues without causing clinical manifestations. It becomes active when body immunity decreases. [2] TB is an important health problem, in Qatar, the trend of extrapulmonary TB is increasing with 53.6% of cases in 2008 [3] while only 29% of cases in 2005 [4] abdominal TB was representing 7.5%.
Abdominal TB is one of the common presentations of extrapulmonary tuberculosis. [5] It can affect gastrointestinal tract, lymph nodes, other abdominal solid organs, peritoneum, and omentum. Presenting symptoms vary according to the site involved. Patients might present with symptoms of intestinal obstruction or acute abdomen as well. [6] Pancreatic TB is a rare entity because the pancreas is biologically protected from MTB infection due to pancreatic enzymes. Thus, most of the cases are secondary to contagious infection from peripancreatic lymph nodes or rarely from hematogenous spread. [7] It poses a clinical dilemma. Clinically and radiologically, it may mimic a pancreatic malignancy. [8] [9] [10] [11] [12] The common presenting features are nonspecific abdominal pain, fever, anorexia and weight loss. [8] Since clinical and radiological features are nonspecific, histology is required for diagnosis. Which can be done through either percutaneous ultrasonography, CT guided biopsy,open/laproscopic biopsy ,or endoscopic ultrasound (EUS). [13, 14] Currently, EUS biopsy is considered the "gold standard" for diagnostic modality for pancreatic mass. [1, 13] Biopsy cytology in pancreatic TB shows granulomatous inflammation, epitheloid histiocytes, plasma cells, and lymphocytes, while acid-fast bacilli are rarely seen. [1, 13] A positive MTB culture or PCR is highly specific but is less sensitive. Once diagnosed, pancreatic TB is treated with standard anti-TB medication for at least 6 month's duration. Symptomatic response and repeat abdominal imaging need it for assessment of response and duration of therapy. [10, 13] Our patient was diagnosed by EUS-guided biopsy showing granulomatous granuloma and positive PCR from TB culture within 2 weeks rifampicin sensitive sand later final culture sensitivity came as fully sensitive MTB. The patient was started on first-line anti-TB medication, and he left back to his home country. Since we do not have a link with the health authorizes in his country to follow-up, the patient we cannot determine the final treatment duration. conclusIon Pancreatic TB is rare disease; however, it should be kept in the differential diagnosis of patient with pancreatic mass, especially people from the endemic area. Clinical suspension of pancreatic TB may guide clinicians to appropriate diagnostic studies including US and management with antituberculosis therapy.
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